Pulmonary Retention of Adipose Stromal Cells Following Intravenous Delivery Is Markedly Altered in the Presence of ARDS by Lu, Hongyan et al.
Delivered by Ingenta to: IUPUI University Library
IP: 134.68.173.249 On: Thu, 09 Mar 2017 15:02:01
Article(s) and/or figure(s) cannot be used for resale. Please use proper citation format when citing this article including the DOI,
Cell Transplantation, Vol. 25, pp. 1635–1643, 2016 0963-6897/16 $90.00 + .00
Printed in the USA. All rights reserved. DOI: http://dx.doi.org/10.3727/096368915X690189
Copyright Ó 2016 Cognizant, LLC. E-ISSN 1555-3892
 www.cognizantcommunication.com
Received September 24, 2015; final acceptance June 2, 2016. Online prepub date: November 25, 2015.
Address correspondence to Natalia V. Bogatcheva, Ph.D., ICVBM, 1481 W 10th Street, C3105, Indianapolis, IN 46202, USA. Tel: (317) 988-4535; 
Fax: (317) 988-9325; E-mail: nbogatch@iu.edu
1635
Pulmonary Retention of Adipose Stromal Cells Following Intravenous 
Delivery Is Markedly Altered in the Presence of ARDS
Hongyan Lu,*†‡§ Todd Cook,*†‡ Christophe Poirier,¶ Stephanie Merfeld-Clauss,*†‡§ 
Irina Petrache,†‡§¶ Keith L. March,*†‡§ and Natalia V. Bogatcheva*†‡§
*Division of Cardiology, Indiana University, Indianapolis, IN, USA
†Indiana Center for Vascular Biology and Medicine, Indiana University, Indianapolis, IN, USA
‡VC-CAST Signature Center, Indiana University, Purdue University, Indianapolis, IN, USA
§Roudebush Veteran Affairs Medical Center, Indianapolis, IN, USA
¶Division of Pulmonary and Critical Care Medicine, Indiana University, Indianapolis, IN, USA
Transplantation of mesenchymal stromal cells (MSCs) has been shown to effectively prevent lung injury in sev-
eral preclinical models of acute respiratory distress syndrome (ARDS). Since MSC therapy is tested in clini-
cal trials for ARDS, there is an increased need to define the dynamics of cell trafficking and organ-specific 
accumulation. We examined how the presence of ARDS changes retention and organ-specific distribution of 
intravenously delivered MSCs isolated from subcutaneous adipose tissue [adipose-derived stem cells (ADSCs)]. 
This type of cell therapy was previously shown to ameliorate ARDS pathology. ARDS was triggered by lipopoly-
saccharide (LPS) aspiration, 4 h after which 300,000 murine CRE+ ADSCs were delivered intravenously. The 
distribution of ADSCs in the lungs and other organs was assessed by real-time polymerase chain reaction (PCR) 
of genomic DNA. As anticipated, the majority of delivered ADSCs accumulated in the lungs of both control and 
LPS-challenged mice, with minor amounts distributed to the liver, kidney, spleen, heart, and brain. Interestingly, 
within 2 h following ADSC administration, LPS-challenged lungs retained significantly lower levels of ADSCs 
compared to control lungs (~7% vs. 15% of the original dose, respectively), whereas the liver, kidney, spleen, and 
brain of ARDS-affected animals retained significantly higher numbers of ADSCs compared to control animals. 
In contrast, 48 h later, only LPS-challenged lungs continued to retain ADSCs (~3% of the original dose), whereas 
the lungs of control animals and nonpulmonary organs in either control or ARDS mice had no detectable levels of 
ADSCs. Our data suggest that the pulmonary microenvironment during ARDS may lessen the pulmonary capil-
lary occlusion by MSCs immediately following cell delivery while facilitating pulmonary retention of the cells.
Key words: Acute respiratory distress syndrome (ARDS); Adipose-derived stem cells (ADSCs); 
Transplantation; Retention
INTRODUCTION
Acute respiratory distress syndrome (ARDS) is a dev-
astating critical condition where lungs fail to oxygenate 
blood due to a massive inflammatory response. ARDS 
patients require ventilation and face 40% mortality in 
cases of severe ARDS1. Even with substantial progress 
reached with improvement of supportive care, the need 
for lung-protective therapy is hard to overestimate2. While 
pharmacological therapies tested so far have not been suc-
cessful in reducing mortality3,4, in the last decade preclini-
cal studies have shown strong promise for mesenchymal 
stem cells (MSCs), including those derived from adipose 
tissue (ADSCs)5,6.
MSC transplantation via intravenous (IV) delivery is 
a minimally invasive procedure; however, it is associated 
with a certain risk of pulmonary capillary bed occlu-
sion and thromboembolism7. As patients with ARDS are 
already at higher risk for thromboemboli8, assessment 
of lung-specific accumulation of transplanted cells and 
dynamics of their retention in lungs and other organs are 
of utmost importance.
To trace transplanted cells, researchers label them with 
fluorophores, such as radioactive or nuclear magnetic res-
onance (NMR) probes. While detection of conventional 
fluo rescent probes presents problems of autofluorescence, 
photobleaching, and short penetration depth9, more advanced 
probes such as infrared quantum dots (QDs)10, and probes 
for positron emission tomography (PET) and magnetic 
resonance imaging (MRI)11 require specialized equipment 
to assess the labeled cell distribution. To overcome this 
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problem, we utilized adipose-derived stem cells (ADSCs) 
isolated from genetically modified mice carrying CRE 
expression under a Tie2 promoter12. As the Tie2 promoter 
is not specific for ADSCs, detection is possible by analysis 
of genomic DNA with CRE-specific primers.
Lungs seem to be privileged organs when it comes to 
the retention of IV-delivered particles11,13, as it represents 
the first capillary bed met by the particles delivered to the 
peripheral vein. Not surprisingly, the first clinical trials 
using MSCs (NCT01775774 at clinicaltrials.gov) and 
ADSCs14 for treatment of ARDS intravenously adminis-
tered the cells. However, one possible complication of IV 
delivery is pulmonary capillary bed occlusion and throm-
boembolism of the lung7; therefore, the dosage and the 
speed of delivery, along with the vasoconstrictive status 
of the patient, should be taken into account.
In the current study, we determined the ability of naive 
and lipopolysaccharide (LPS)-primed lungs (and other 
organs) to retain IV-delivered ADSCs. This study had 
three objectives: (1) to determine if ADSC retention in 
lungs is increased in ARDS; (2) to determine the length 
of ADSC retention in ARDS lungs; and (3) to determine 
if ADSCs are redistributed to other organs. To understand 
ARDS-specific dynamics of cell distribution, we ana-
lyzed cardiac output and parameters indicative of pulmo-
nary pressure in LPS-challenged mice. The results of our 
study are informative of the safety of IV ADSC therapy 
for ARDS and the dynamics of ADSC retention in lungs 
for future therapy optimization.
MATERIALS AND METHODS
Materials
Escherichia coli LPS 0127:B8 with the lot activity of 
3,000,000 U/mg and fluorescein isothiocyanate (FITC)–
dextran (40 kDa) were purchased from Sigma-Aldrich 
(St. Louis, MO, USA).
Animals
Twelve-week-old female C57BL/6 mice were purchased 
from Harlan Laboratories (Indianapolis, IN, USA). Tie2 
CreERT2 mice were generously provided by Dr. Carlesso 
from Indiana University. Transgenic mice on the origi-
nal back ground12 received from Dr. Carlesso (Indiana 
University) had been bred with C57BL/6 for two gen-
erations, and then the strain was maintained as a closed 
colony by breeding transgenic males with nontransgenic 
females from the same colony. All animal procedures were 
approved by the Indiana University Institutional Animal 
Care and Use Committee (IACUC) and conformed to the 
requirements of the Animal Welfare Act.
Cell Culture
Murine ADSCs (mADSCs) were isolated from subcu-
taneous fat pads of female heterozygous Tie2CreERT2 
carriers (3–4 months old). Briefly, fat was excised from 
the isoflurane-anesthetized animals (n = 3), minced, and 
digested with 2 mg/ml collagenase type 1 (Worthington 
Biochemical, Lakewood, NJ, USA) at 37°C. Digested 
tissue was centrifuged at 300 × g to separate floating 
adipocytes. Pellets containing the stromal vascular frac-
tion were resuspended in Endothelial Basal Medium-2 
(EBM2; Lonza, Bazel, Switzerland) with 5% fetal 
bovine serum (FBS; Lonza), filtered through a 100-µm 
nylon filter, and centrifuged again at 300 × g. Cells were 
resuspended in Endothelial Growth Medium EGM2-MV 
(Lonza), allowed to adhere to plastic, and propagated 
until the third passage (P3) at 37°C in a humidified atmo-
sphere of 5% CO2 and 95% O2. Before injection, cells 
were trypsinized (Lonza) and resuspended in EBM2 at a 
concentration of 3 × 106 cells/ml.
Cell Tracing Experiment
LPS (2 mg/kg) or an equal volume of saline was deliv-
ered by oropharyngeal aspiration to isoflurane-anesthetized 
C57BL/6 mice (20–25 g) as previously described15. Control 
mice received an equal volume of saline. ADSCs derived 
from Tie2CreERT2 mice12 (P3) were resuspended at 3 × 106 
cell/ml in EBM2 containing 6.25 mg/ml FITC–dextran, 
and injected into the tail vein (300,000 cells per mouse) 
4 h after LPS administration. To ascertain the efficiency of 
cell injection, 10 min after injection blood was sampled 
from the saphenous vein and analyzed for FITC fluores-
cence. Animals anesthetized with isoflurane were exsan-
guinated; lung, heart, spleen, kidney, brain, and liver were 
collected immediately after cell injection, or 2, 24, or 48 h 
later (n = 4 for each time group). Organs were snap frozen 
in liquid nitrogen. Minced organs were subjected to com-
plete digestion with enzymes from a mini total RNA kit 
for tissue (IBI Scientific, Peosta, IA, USA), and genomic 
DNA free of mRNA was extracted. DNA was analyzed 
with quantitative real-time polymerase chain reaction 
(qRT-PCR) for the presence of CRE transgene, using 
D19Mit1 as a loading control. The following primers were 
used: CRE, 5¢-GCGGTCTGGCAGTAAAAACTATC-3¢ 
and 5¢-GTGAAACAGCATTGCTGTCACTT-3¢; D19Mit1: 
5¢-AATCCTTGTTCACTCTATCAAGGC-3¢ and 5¢-CAT 
GAAGAGTCCAGTAGAAACCTC-3¢.
To establish that there was no tissue-specific interfer-
ence with the qPCR reaction, calibration curves were cre-
ated for DNA from each organ of interest isolated directly 
from Tie2CreERT2 animals. The quantity of CRE+ cells 
per organ was calculated on the basis of the knowledge 
that the mouse cell contains 5.6 pg DNA/cell, and using the 
difference in Ct to calculate the difference in the content of 
CRE+ genomic DNA between organs from Tie2CreERT2 
heterozygous animals and organs from C57BL/6 mice 
injected with cells from Tie2CreERT2 heterozygous ani-
mals. To enable calculation of the amount of CRE+ cells 
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per the amount of DNA loaded into the PCR machine to 
the amount of CRE+ cells per organ, we first established 
conditions assuring that total DNA digestion and extrac-
tion were achieved from each analyzed organ aliquot. Each 
organ was weighed and minced; two aliquots of minced 
tissue from each organ were weighed and fully digested 
to extract genomic DNA. DNA yield per organ was cal-
culated. For the analysis of CRE+ cells in lungs, 25 ng of 
extracted DNA was analyzed by StepOnePlus Real-Time 
PCR (Applied Biosystems, Foster City, CA, USA); for the 
rest of the organs, 500 ng was loaded to increase the sen-
sitivity of detection. Each DNA sample was analyzed with 
CRE-specific and D19Mit1-specific primers; each PCR 
analysis included DNA from the specific CRE+ organ. To 
equalize values generated in parallel PCR runs, we normal-
ized the Ct(cre organ) value as Ct(cre organ) × Ct(cre+)/Ct(D19 organ). To 
calculate the amount of CRE+ cells per loaded amount 
of DNA, we divided total expected amount of cells (for 
example, 500 ng is expected to contain DNA from 
89,286 cells) by 2 [normCt(cre organ )-Ct(cre+)]. To arrive at the total 
number of cells per organ, we back calculated the amount 
of cells per loaded DNA sample to the total DNA yield 
per organ.
Echocardiography
It was recently shown that a parameter known as ratio 
between pulmonary acceleration time and ejection time 
(PAT/PET) is negatively correlated with right ventricle 
systolic pressure (RVSP)16. While RVSP measurement is 
an invasive procedure, PAT/PET can be easily assessed by 
echocardiography. Transthoracic closed-chest echocardio-
graphy was performed in isoflurane-anesthetized ani-
mals using 40-MHz solid-state transducers (Vevo 2100; 
VisualSonics, Toronto, ON, Canada). Two-dimensional 
images of pulmonary infundibulum and pulsed wave 
Doppler recordings of the pulmonary blood flow were 
obtained from the long axis view; the left ventricle was 
imaged from a short axis view. Color Doppler was used to 
visualize the highest area of flow in the pulmonary artery 
(PA); the pulsed wave Doppler was collected at this 
location. Measurements of PAT and PET were performed 
offline. PAT was calculated as time from the onset of 
pulmonary flow to peak velocity by pulsed wave Doppler 
recording. PET was calculated as the time interval between 
the onset and the end of the systolic flow velocity. Cardiac 
output was calculated as a difference between the systolic 
and diastolic volume of the left ventricle, multiplied by the 
heart rate (n = 3 was for control and LPS-treated groups).
Statistical Analysis
Quantitative data are presented as mean ± standard error 
of the mean (SEM). Statistical analysis was performed 
by t-test and t-test with Welch’s correction (unequal vari-
ance) using Origin 8.0 (OriginLab, Northampton, MA, 
USA) or GraphPad Prism6 (GraphPad Software, San 
Diego, CA, USA) software. A value of p < 0.05 was con-
sidered statistically significant.
RESULTS
Study Design
Previously, we have shown that mice subjected to 
oropharyngeal LPS aspiration manifest severe hypother-
mic reactions 4 h after LPS administration17. That point 
was chosen as a “seek care” point to administer ADSC 
therapy. The current study was designed on the basis of 
our previous scheme of therapeutic delivery in order to 
understand the dynamics of ADSC retention in control 
mice and mice affected by LPS-induced lung injury. As 
presented in Figure 1, LPS or saline was delivered into 
the lungs through oropharyngeal aspiration. Intravenous 
ADSC injections were performed 4 h after LPS deliv-
ery. Since injections into the murine tail vein are often 
associated with incomplete transfer of injected mate-
rial, we had to implement control over the efficiency 
of cell transfer. To achieve that, ADSCs were deliv-
ered in the media containing FITC–dextran. Sampling 
of blood from the saphenous vein 10 min after ADSC 
delivery allowed us to assess plasma fluorescence and 
exclude from analysis tissues from mice with plasma 
Figure 1. Timeline of the in vivo study design. Times at which mice were sacrificed and tissues collected for analysis are shown with 
black rectangles.
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fluorescence levels less than 70% of the mean plasma 
fluorescence level.
Retention of IV-Delivered ADSCs in Lungs 
and Other Organs
To analyze distribution of ADSCs in different organs 
of naive and LPS-challenged mice, we traced ADSCs 
isolated from genetically modified mice carrying a CRE 
transgene. Use of CRE+ ADSCs gave us an opportunity 
to detect cells by the analysis of genomic DNA from the 
organ of interest. Comparison of titration curves for CRE 
transgene with titration curves for D19Mit1 marker (MGI 
ID: 91215, one locus per genome) revealed the pres-
ence of ³10 loci of CRE transgene in the genome of the 
donor transgenic mice (Fig. 2A–C), which significantly 
improved our ability to detect CRE+ cells in organs with 
limited CRE+ cell distribution.
Analysis of lungs from ADSC-injected mice receiving 
saline showed that approximately 10–15% of the 300,000 
injected cells were retained in lungs for at least 2 h fol-
lowing cell injection. This amount was markedly reduced 
in the next 24 h, and levels became negligible at 48 h 
postinjection (Fig. 3A). On the contrary, LPS-challenged 
lungs retained significantly fewer cells immediately after 
injection (less than 3% of injected dose). This level was 
increased to ~7% within the next 2 h, remained stable for 
the following 24 h, and was still substantial (~3%) 48 h 
postinjection. Analysis of the spleen, liver, kidneys, brain, 
and heart demonstrated minor cell retention compared to 
the lung (Fig 3). We did not detect evidence of CRE+ cell 
Figure 2. Real-time polymerase chain reaction (PCR) serial dilution standard curves for CRE transgene and D19Mit1 marker. 
Standard curves were constructed with CRE-specific primers for the serial dilutions of genomic DNA from the (A) lung (squares), 
spleen (circles), and heart (triangles), and (B) kidney (squares), liver (circles), and brain (triangles). (C) Parallel standard curves were 
constructed with D19Mit1-specific primers for lung (squares) and spleen (circles). DNA (500 ng) was loaded at the lowest dilution 
point. Estimated cell number for each dilution is shown on the plot. CRE is detected at higher dilution rates than D19Mit1 (one locus 
per genome), suggesting incorporation of multiple CRE copies at multiple loci. NS stands for not significant level of detection.
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translocation from the lung to other organs in the period 
between 24 and 48 h, when the level of CRE+ cells in 
the lungs was significantly decreased. Interestingly, the 
majority of analyzed organs show control/LPS cell ratio 
opposite to the one observed in the lung 2 h postinjection. 
CRE+ cell content in the spleen, liver, kidney, and brain of 
mice challenged with LPS was higher than that in organs 
of control mice. Importantly, 48 h postinjection, the only 
organ still showing significant CRE+ cell retention was 
the LPS-challenged lung.
Assessment of Hemodynamics in ARDS Mice
To understand why LPS-primed lungs retain fewer 
ADSCs immediately following ADSC administration and 
2 h later, we assessed parameters related to pulmonary 
pressure and cardiac output. Figure 4A shows that mice 
subjected to LPS aspiration experienced severe reductions 
of PAT/PET 4 h after LPS administration, indicative of an 
increase in pulmonary pressure. We have also observed 
that 4 h after LPS administration, mice manifest marked 
reductions in heart rate (Fig. 4B). Although significant 
changes in stroke volume were not observed until 24 h 
after LPS administration (Fig. 4C), reduction in heart rate 
leads to a significant reduction of cardiac output 4 h after 
LPS administration (Fig. 4D).
DISCUSSION
This is the first study to demonstrate that conditions 
associated with the onset of ARDS lower the possibility 
of immediate ADSC retention in the lungs and complica-
tions, which may be associated with capillary occlusion by 
cells retained in the lungs. Abundant data in the literature 
show that the IV route of cell delivery renders preferential 
cell retention in the lungs immediately after injection10,11,13. 
Figure 4. PAT/PET (A), heart rate (B), stroke volume (C), and cardiac output (D) for mice receiving saline (gray squares) or LPS 
(black circles) via oropharyngeal aspiration (n = 3 per group). Black lines indicate periods of dark (12-h light/dark cycle). First time 
point of the day was recorded at 8:00 a.m. Arrows indicate a point in time when adipose-derived stem cells (ADSCs) would be deliv-
ered. *p < 0.05 between responses of control animals and animals exposed to LPS.
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The objective of this study was to compare distribution of 
cells to naive and LPS-challenged lungs, as well as other 
internal organs including the brain. The information gained 
is quite critical for the development and optimization of 
ARDS therapy; it also offers insights for the physicians 
considering ADSC application for the inflammatory patho-
logical conditions of the other organs.
We observed that approximately 10% to 15% of injected 
ADSCs were retained in healthy murine lungs 0–2 h after 
bolus delivery of 300,000 cells. This number was some-
what lower than previously reported in the literature11, 
although the number of cells per injection, the animal 
model, and the method of detection probably affected the 
outcome and analysis. Importantly, we observed that LPS-
primed lungs retained approximately half the amount of 
ADSCs found in healthy lungs within the first 2 h after 
injection. To understand why the amount of cells retained 
in LPS-primed lungs is reduced, we assessed the effect 
of aspirated LPS on hemodynamics. Although data in the 
literature consistently link systemic delivery of LPS to 
an increase in pulmonary artery pressure18,19, studies on 
intratracheal administration of LPS are rather limited and 
show dependence of LPS-induced pulmonary hyperten-
sion on the presence of other triggers20. Keeping in mind 
that LPS administration to the lungs mimics ARDS caused 
by pneumonia rather than sepsis and therefore may have 
different effects than systemic LPS administration, we 
undertook the study of pulmonary hemodynamics fol-
lowing LPS aspiration. Our data demonstrate that LPS-
challenged mice manifest significant reductions in PAT/
PET ratios, indicative of an increase in pulmonary artery 
pressure16. LPS-challenged mice also manifest markedly 
reduced cardiac output 4 h post-LPS administration. All 
of these changes coincide with the peak of hypothermic 
shock17, which was used earlier to choose the point for 
therapeutic intervention. We are fully aware that these 
initial changes in hemodynamics reflect a direct reaction 
of the lungs to LPS rather than ARDS-related changes. 
However, cardiac output remains significantly decreased 
24 h post-LPS challenge (Fig. 4), when ARDS is fully 
developed in this model17. We believe that significant 
reductions in cardiac output observed in our model make 
it clinically relevant to the changes in cardiac output 
observed in ARDS patients. Increased pulmonary vascu-
lar resistance in ARDS is often linked to elevated right 
ventricular afterload, which may produce right ventricu-
lar dysfunction and failure21,22. Not surprisingly, agents 
reducing pulmonary artery pressure, such as nitric oxide 
(NO), also increase cardiac output when acute right heart 
failure is present23,24, linking changes in cardiac output to 
both the severity of ARDS and the efficiency of therapeu-
tic interventions.
While pulmonary vasoconstriction is likely to affect 
larger vessels and not have a substantial effect on the ability 
of ADSCs to circulate freely, the decreased rate at which 
bolus-delivered ADSCs are perfused through the pulmo-
nary capillary bed is likely to reduce the incidence of steric 
capillary occlusion by large particles such as ADSCs. Even 
though MSCs, whether bone marrow or adipose derived, are 
unlikely to be delivered to ARDS patients as a rapid bolus, 
current safety studies opt for IV delivery of ADSCs or bone 
marrow-derived MSCs (BM-MSCs). For instance, one 
study of ADSC transplantation for ARDS utilized a dose of 
106 cells/kg delivered over a period of 1 h14. Another study 
of BM-MSC transplantation for ARDS (NCT01775774 at 
clinicaltrials.gov) utilized 1, 5, and 10 × 106 cells/kg dose 
delivered over a period of 60–80 min25. For comparison, 
in our study, 15 × 106 cells/kg rapid bolus delivery was 
tested. The fact that the reported safety study14 suggested 
an increase in cell dosage in order to achieve a beneficial 
effect on ARDS calls for increased attention to the rate 
of cell delivery, which may increase cell retention in the 
lungs and the possibility of pulmonary bed occlusion. In 
light of the data presented here, pulmonary hypertension 
and the reduction of cardiac output in ARDS patients21,22, 
also observed in our model at the time of cell delivery, may 
reduce the risk of capillary occlusion due to steric blocking 
of the capillary bed with intravenously delivered cells.
Importantly, the dynamics of cell distribution change 
dramatically in the following 48 h. Twenty-four hours 
after ADSC administration, control lungs demonstrated 
marked reduction of ADSC levels, reaching negligible 
levels at 48 h. On the contrary, LPS-challenged lungs 
retained 6% and 3% of the delivered ADSC dose 24 and 
48 h postinjection, respectively. These data are consis-
tent with the data of others showing ~1% retention after 
72 h26. Previously, we had shown a strong inflammatory 
response in LPS-challenged lungs 24 and 48 h post-LPS 
administration17. We speculate that the inflammation con-
tributes to the sustained retention of ADSCs in ARDS-
affected versus control lungs.
Dissimilar to the lung, other organs had only minor 
retention of ADSCs following IV delivery. These data 
suggest that when direct organ targeting is needed, cells 
have to be delivered locally rather than peripherally. On 
the other hand, an increase in mortality was shown when 
stem cells were delivered in the left atrium, possibly 
due to the embolism of cardiac circulation11. We failed 
to detect redistribution of ADSCs to the spleen or liver, 
as shown in other reports27. Possible redistribution to the 
thoracic lymph nodes28 was not analyzed here.
A low percentage of stem cell engraftment in the lungs 
compared to the original delivered dose led others to spec-
ulate that the effect on ARDS is mostly paracrine26. That 
is, that the effects were mediated by the factors secreted 
by stem cells engrafted elsewhere. Although we cannot 
completely exclude this possibility, our data show that 
the time-dependent curves of ADSC distribution in other 
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organs follow the time-dependent curve of ADSC distri-
bution in the lungs, with a higher cell level in the first 2 h 
following injection and a decrease in the following 48 h. 
Our data clearly show that ARDS-affected lungs are the 
only organs that harbor a substantial amount of ADSCs 
48 h postinjection, making pulmonary-engrafted ADSCs 
the primary source of the therapeutic material.
In conclusion, we demonstrated that ARDS-affected 
lungs retain a reduced amount of IV-delivered ADSC bolus 
within the first 2 h after delivery. On the contrary, 48 h later 
only ARDS-affected lungs retain a substantial amount of 
ADSCs. No evidence of significant cell distribution to other 
organs at this time point was found in control mice or mice 
with ARDS. Our findings provide novel insights necessary 
for the development and optimization of cell-based therapy 
for ARDS.
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